BACKGROUND: Non-specific bronchial hyperresponsiveness (NSBH) is a known predictor of accelerated rate of decline in lung function in smokers. Polymorphisms of the beta(2) adrenergic receptor (ADRB2) have previously been associated with NSBH and bronchodilator response (BDR) in asthmatics. Based on these associations, we hypothesised that ADRB2 polymorphisms would be associated with NSBH and BDR as well as an accelerated rate of decline in lung function among smokers. METHODS: The prevalence of two ADRB2 polymorphisms, Arg16-->Gly and Gln27-->Glu, was examined in 587 smokers chosen from the NHLBI Lung Health Study for having the fastest (n=282) and slowest (n=305) 5 year rate of decline in forced expiratory volume in 1 second (FEV(1); mean DeltaFEV(1) -4.14 and +1.08% predicted/year, respectively). RESULTS: Contrary to our hypothesis, no ADRB2 allele or haplotype was associated with NSBH, BDR, or rate of decline in lung function. However, there was a significant negative association between heterozygosity at position 27 and a fast decline in lung function (adjusted odds ratio 0.56, 95% CI 0.40 to 0.78, p=0.0007). CONCLUSIONS: Heterozygosity at position 27 may be protective against an accelerated rate of decline in lung function. The polymorphism at position 16 does not contribute to the rate of decline in lung function, measures of NSBH, or BDR in smokers.
BACKGROUND: Non-specific bronchial hyperresponsiveness (NSBH) is a known predictor of accelerated rate of decline in lung function in smokers. Polymorphisms of the beta(2) adrenergic receptor (ADRB2) have previously been associated with NSBH and bronchodilator response (BDR) in asthmatics. Based on these associations, we hypothesised that ADRB2 polymorphisms would be associated with NSBH and BDR as well as an accelerated rate of decline in lung function among smokers. METHODS: The prevalence of two ADRB2 polymorphisms, Arg16-->Gly and Gln27-->Glu, was examined in 587 smokers chosen from the NHLBI Lung Health Study for having the fastest (n=282) and slowest (n=305) 5 year rate of decline in forced expiratory volume in 1 second (FEV(1); mean DeltaFEV(1) -4.14 and +1.08% predicted/year, respectively). RESULTS: Contrary to our hypothesis, no ADRB2 allele or haplotype was associated with NSBH, BDR, or rate of decline in lung function. However, there was a significant negative association between heterozygosity at position 27 and a fast decline in lung function (adjusted odds ratio 0.56, 95% CI 0.40 to 0.78, p=0.0007). CONCLUSIONS: Heterozygosity at position 27 may be protective against an accelerated rate of decline in lung function. The polymorphism at position 16 does not contribute to the rate of decline in lung function, measures of NSBH, or BDR in smokers.
Authors: J W Holloway; P R Dunbar; G A Riley; G M Sawyer; P F Fitzharris; N Pearce; G S Le Gros; R Beasley Journal: Clin Exp Allergy Date: 2000-08 Impact factor: 5.018
Authors: Z Wang; C Chen; T Niu; D Wu; J Yang; B Wang; Z Fang; C N Yandava; J M Drazen; S T Weiss; X Xu Journal: Am J Respir Crit Care Med Date: 2001-05 Impact factor: 21.405
Authors: C M Drysdale; D W McGraw; C B Stack; J C Stephens; R S Judson; K Nandabalan; K Arnold; G Ruano; S B Liggett Journal: Proc Natl Acad Sci U S A Date: 2000-09-12 Impact factor: 11.205
Authors: M Ulbrecht; M T Hergeth; M Wjst; J Heinrich; H Bickeböller; H E Wichmann; E H Weiss Journal: Am J Respir Crit Care Med Date: 2000-02 Impact factor: 21.405
Authors: Melanie C Matheson; Justine A Ellis; Joan Raven; David P Johns; E Haydn Walters; Michael J Abramson Journal: J Hum Genet Date: 2006-09-01 Impact factor: 3.172
Authors: Kathryn Blake; James D Cury; Jobayer Hossain; Kelan Tantisira; Jianwei Wang; Edward Mougey; John Lima Journal: Pulm Pharmacol Ther Date: 2013-02-04 Impact factor: 3.410